Early hypertransaminasemia after kidney transplantation: Significance and evolution according to donor type

Abstract

Early hypertransaminasemia after kidney transplantation (KT) is frequent. It has been associated with the crosstalk produced between the liver and the kidney in ischemia‐reperfusion situations. However, the influence of the donor type has not been evaluated. We present a retrospective study analyzing the increase in serum aspartate aminotransferase/alanine aminotransferase (AST/ALT) during the first three months post‐KT in 151 recipients who received thymoglobulin as induction therapy, either from brain‐death donors (DBD, n = 75), controlled circulatory death donors (cDCD, n = 33), or uncontrolled DCD (uDCD, n = 43). Eighty‐five KT recipients from DBD who received basiliximab were included as controls. From KT recipients who received thymoglobulin, 33.6/43.4% presented with an increase in AST/ALT at 72 h post‐KT, respectively. Regarding donor type, the percentage of recipients who experienced 72 h post‐KT hypertransaminasemia was higher in uDCD group (65.1/83.7% vs. 20.3/26% in DBD and 20.7/27.6% in cDCD, p < 0.001). Within the control group, 9.4/12.9% of patients presented with AST/ALT elevation. One month after transplant, AST/ALT values returned to baseline in all groups. The multivariate analysis showed that uDCD recipients had 6‐ to 12‐fold higher risk of developing early post‐KT hypertransaminasemia. Early post‐KT hypertransaminasemia is a frequent and transient event related to the kidney donor type, being more frequent in uDCD recipients.